Abstract: Methods involving: A) placing one or more solid materials on a skin surface; after step A), B) electrostatically spraying a composition X comprising (a) one or more volatile substances selected from water, an alcohol, and a ketone and (b) a polymer having a coating forming ability directly on the skin to thereby form a coating on the skin surface; and after step B) or before step A), C) applying a composition Y, other than the composition X, comprising one or more components selected from the group consisting of (c) an adhesive polymer and (d) an oil component (d) to the skin, are useful for producing a wearable coating having a solid material fixed on skin.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
May 24, 2022
Assignee:
KAO CORPORATION
Inventors:
Nobuyuki Asami, Asuka Imai, Michael Rosner
Abstract: A composition provides a protective barrier and includes glyceryl dibehenate, tribehenin, and glyceryl behenate, a surfactant that includes glyceryl stearate, one or more fatty compounds, and one or more triglyceride. The composition optionally includes a hydrating agent and may be essentially free of or is devoid of one or more of petrolatum, mineral oil and water. The composition provides occlusivity and hydration effects that are comparable to compositions that include one or more of petrolatum, mineral oil and lanolin.
Type:
Grant
Filed:
September 25, 2018
Date of Patent:
May 17, 2022
Assignee:
L'OREAL
Inventors:
Zachary Maron, Paul P. Bonvallet, Susan Halpern Chirch, Lilian Josephson
Abstract: The present invention provides a productivity enhancing agent, a wasting rate-reducing agent, an ameliorating agent for ascites, emaciation, or maldevelopment, and a prophylactic or therapeutic agent for inflammation or colibacillosis for use in poultry such as chickens for meat, which comprises unheated cashew nut shell liquid, heated cashew nut shell liquid, anacardic acid, cardanol, and/or cardol.
Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.
Abstract: A pulverulent semisynthetic material, derived from a natural marine biomaterial, namely the aragonitic inner layer of the shell of bivalve molluscs selected from Pinctadines, notably Pinctada maxima, margaritifera, and Tridacnes, notably Tridacna gigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopus, Hippopus porcelanus, in pulverulent form, with the addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation.
Abstract: Provided is a method for preparing an oil-in-water type emulsion composition, the method comprising a step for stirring and emulsifying a composition containing components (A), (B), (C) and (D) below and then treating under a high shear pressure of 30-300 Mpa, wherein (A) is 5-35 mass % of an acrylic-silicone graft copolymer, (B) is 5-35 mass % of volatile oil, (C) is 2-15 mass % of polyoxyethylene sorbitan fatty acid ester having average addition mole number of ethylene oxide (EO) of 10 or more and HLB of 11 or more, and (D) is 15-88 mass % of water.
Abstract: Methods involving: A) placing one or more solid materials on a skin surface; after step A), B) electrostatically spraying a composition X comprising (a) one or more volatile substances selected from water, an alcohol, and a ketone and (b) a polymer having a coating forming ability directly on the skin to thereby form a coating on the skin surface; and after step B) or before step A), C) applying a composition Y, other than the composition X, comprising one or more components selected from the group consisting of (c) an adhesive polymer and (d) an oil component (d) to the skin, are useful for producing a wearable coating having a solid material fixed on skin.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
April 5, 2022
Assignee:
KAO CORPORATION
Inventors:
Nobuyuki Asami, Asuka Imai, Michael Rosner
Abstract: The present invention relates to a process for manufacturing porous silica particles comprising at least one bioactive compound, whereby the particles are adapted for lung, nasal, sublingual and/or pharyngeal delivery of said at least one bioactive compound and have an MMAD between 0.5 and 15 ?m with a GSD less than 2.5. The invention also relates to a pharmaceutical composition comprising said silica particles and a use of the silica particles in the diagnoses, prevention and/or treatment of local and/or systemic disorders, such as disorders of the lung, nose, sublingual and/or pharynx.
Type:
Grant
Filed:
May 3, 2018
Date of Patent:
March 29, 2022
Assignee:
NANOLOGICA AB
Inventors:
Chunfang Zhou, Adam Feiler, Paulina Paszkiewicz, Xin Xia
Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
Type:
Grant
Filed:
October 9, 2015
Date of Patent:
March 8, 2022
Assignee:
DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.
Inventors:
Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Giuseppe Granata, Patrizia Saladino, Clara La Marco, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
Type:
Grant
Filed:
August 3, 2020
Date of Patent:
February 22, 2022
Assignee:
DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.
Inventors:
Anna Rita Blanco, Maria Luisa Bondiā², Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Guiseppe Granata, Patrizia Saladino, Clara La Marca, Irene Deidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
Abstract: Provided herein are nutritional, or therapeutic, compositions and methods of use in primarily treating kidney patients suffering from low serum albumin. The compositions are divided into four formulations, comprising: 1) the magnesium salt and/or the calcium salt of the alpha keto acids of: ?-leucine, ?-valine, ?-isoleucine, ?-phenylalanine, ?-hydroxy methionine; and/or ?-tryptophan, and/or ?-tyrosine; 2) L-lysine monoacetate, L-threonine; and/or 3) histidine, tryptophan, and tyrosine, as amino acids or base acids. The specific formulation administered depends in part upon which stage 2-5 of renal disease the patient has. The invention further comprises methods of treatment of disorders associated with low serum albumin using the composition as an over-the-counter pill. The patient's serum albumin is tested on a periodic basis and the selected composition and dose are adjusted accordingly.
Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.
Type:
Grant
Filed:
June 16, 2020
Date of Patent:
February 15, 2022
Assignees:
Memorial Sloan Kettering Cancer Center, Cornell University
Inventors:
Michelle S. Bradbury, Ulrich Wiesner, Michael Overholtzer, Howard Scher, Kai Ma
Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.
Type:
Grant
Filed:
April 8, 2019
Date of Patent:
February 15, 2022
Assignee:
Nova Southeastern University
Inventors:
Mutasem Rawas-Qalaji, Ousama Rachid, Keith Simons, Estelle Simons
Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
Type:
Grant
Filed:
June 18, 2019
Date of Patent:
January 25, 2022
Assignee:
Amneal Complex Products Research LLC
Inventors:
Siva Ram Kiran Vaka, Namdev B. Shelke, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.
Type:
Grant
Filed:
November 4, 2020
Date of Patent:
December 21, 2021
Assignee:
DSM IP ASSETS B.V.
Inventors:
George Mihov, Guy Draaisma, Silvana Rensina Antonnietta Di Silvestre, Tristan Handels
Abstract: A composition suitable for application as a nail polish, the composition comprising: an alcohol solvent; ethylcellulose, in an amount that is about 1.0% by weight of the final composition; a film forming agent that includes maleic acid monobutyl ester-vinyl methyl ether copolymer, and maleic acid monoethyl ester-vinyl methyl ether copolymer, in an amount that is at least 40% by weight of the final composition; isostearyl alcohol, in an amount that is about 3.0% by weight of the final composition; a plasticizer in the form of a citric acid ester, in art amount that is about 1.0% by weight of the final composition; a colorant and a fragrance. This composition is suitable for application to a human nail.
Abstract: The present invention provides a method for preparing an injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel. The injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits superior biocompatibility through addition of TEMPO-oxidized cellulose nanofibers, and excellent cell proliferation and bone regeneration through cellular interaction, and is gelled in vivo, thus being highly useful as a filler for wound healing and bone regeneration. In addition, the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits excellent porosity, has an interconnected structure and is thermogelling, based on thermosensitivity of undergoing a sol-gel transition depending on temperature, thus inducing rapid gelation in vivo and facilitating bone regeneration upon implantation in vivo.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
November 16, 2021
Assignees:
SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION, NATIONAL INSTITUTE OF FOREST SCIENCE
Abstract: The object of the present invention is to provide a therapeutic agent for hyperphosphatemia capable sufficiently decreasing a serum phosphorus concentration with a small dose. The present invention provides a therapeutic agent for hyperphosphatemia, which comprises, as an active ingredient, a particle containing certain crosslinked polymer (preferably crosslinked polyallylamine).
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
October 19, 2021
Assignees:
FUJIFILM Corporation, Kyowa Kirin Co., Ltd.
Abstract: The invention provides formulations and a process for disinfection, cleansing, and establishing a residual biostatic surface protection for dentures and removable oral appliances. These appliances include complete and partial dentures, removable dental applications, and other products used in an individual's mouth.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
September 14, 2021
Assignee:
CLEARSTREAM TECHNOLOGIES, LLC
Inventors:
Anthony L Daddona, III, James Praechtl, Daniel Spagnoli, William Spilfogel, Simpson E. Adams, III, Rebecca L Lister
Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.